Organon OGN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Arcoxia | $263M+1.9% | $266M-1.8% | $255M-2.7% | $253M-1.6% | $258M-1.1% | |
| Atozet | $333M-20.5% | $325M-31.4% | $335M-35.5% | $365M-29.8% | $419M-19.9% | |
| Brenzys | $86M+28.4% | $80M+3.9% | $73M-19.8% | $77M0.0% | $67M-14.1% | |
| Clarinex | $120M-2.4% | $123M-2.4% | $120M-6.3% | $122M-5.4% | $123M-7.5% | |
| Cozaar/Hyzaar | $221M-4.3% | $219M-9.9% | $223M-7.9% | $227M-9.6% | $231M-11.8% | |
| Diprospan | $155M+9.9% | $150M+7.1% | $149M+9.6% | $145M+11.5% | $141M+34.3% | |
| Dulera | $145M-23.7% | $153M-24.6% | $170M-15.4% | $184M-8.9% | $190M-6.4% | |
| Emgality | $196M+51.9% | $174M+62.6% | $163M+136% | $141M+253% | $129M+1,190% | |
| Follistim AQ | $257M-1.2% | $265M+11.8% | $273M+7.5% | $272M+11.0% | $260M+2.8% | |
| Fosamax | $139M-4.1% | $143M-5.9% | $146M-2.0% | $144M-5.3% | $145M-9.9% | |
| Ganirelix Acetate Injection | $99M-7.5% | $100M-8.3% | $103M-1.0% | $107M+3.9% | $107M-2.7% | |
| Hadlima | $249M+56.6% | $229M+61.3% | $204M+67.2% | $181M+101% | $159M+130% | |
| Jada | $63M0.0% | $73M+19.7% | $71M+29.1% | $67M+28.8% | $63M+28.6% | |
| Marvelon/Mercilon | $114M-18.6% | $127M-5.2% | $134M-4.3% | $132M-6.4% | $140M+8.5% | |
| Nasonex | $256M-5.5% | $263M-4.7% | $274M+1.9% | $277M+4.1% | $271M-0.4% | |
| Nexplanon/Implanon NXT | $874M-11.9% | $921M-4.5% | $970M+3.6% | $990M+8.4% | $992M+12.1% | |
| NuvaRing | $94M-5.1% | $92M-20.0% | $101M-21.7% | $98M-34.2% | $99M-40.4% | |
| Ontruzant | $86M-28.3% | $99M-29.8% | $114M-32.5% | $103M-45.5% | $120M-31.0% | |
| Other Biosimilars | $52M— | $33M— | $28M— | $26M— | —— | |
| Other Cardiovascular | $123M-1.6% | $125M-6.0% | $131M+4.0% | $127M-8.0% | $125M-12.0% | |
| Other Non-Opiod Pain, Bone and Dermatology | $300M+4.2% | $300M+2.7% | $296M+1.4% | $290M-0.7% | $288M+1.1% | |
| Other Respiratory | $50M-13.8% | $51M-5.6% | $57M+18.8% | $59M+9.3% | $58M0.0% | |
| Other | $347M+8.1% | $338M+3.4% | $340M+6.6% | $336M+8.0% | $321M-0.6% | |
| Other | $77M-29.4% | $81M-30.2% | $96M-8.6% | $101M-1.9% | $109M-2.7% | |
| Other Women's Health | $177M+13.5% | $174M+11.5% | $167M+5.7% | $164M+8.6% | $156M+2.6% | |
| Propecia | $123M+7.9% | $119M+7.2% | $123M+9.8% | $118M+11.3% | $114M0.0% | |
| Proscar | $99M+7.6% | $97M+3.2% | $95M+3.3% | $91M-3.2% | $92M-4.2% | |
| Renflexis | $251M-4.2% | $251M-8.4% | $254M-11.5% | $256M-9.9% | $262M-8.1% | |
| Rosuzet | $26M-29.7% | $24M-51.0% | $29M-46.3% | $34M-43.3% | $37M-45.6% | |
| Singulair | $218M-35.1% | $252M-30.0% | $277M-29.0% | $309M-22.0% | $336M-12.3% | |
| Vtama | $129M+258% | $128M+967% | $101M— | $67M— | $36M— | |
| Vytorin | $98M-4.9% | $100M-7.4% | $101M-9.0% | $102M-13.6% | $103M-19.5% | |
| Zetia | $344M+8.2% | $342M+7.9% | $329M+6.5% | $317M+6.7% | $318M+0.3% | |
| Revenue by Geography | ||||||
| Asia Pacific and Japan | $975M-3.9% | $1B-4.9% | $996M-6.7% | $1.01B-7.9% | $1.02B-7.1% | |
| China | $819M-3.1% | $829M-2.1% | $840M+0.4% | $833M+0.7% | $845M0.0% | |
| Europe and Canada | $1.65B-2.1% | $1.62B-8.2% | $1.63B-7.1% | $1.65B-3.6% | $1.69B-2.0% | |
| Latin America, Middle East, Russia, and Africa | $1.08B+8.0% | $1.07B+3.8% | $1.08B+3.0% | $1.03B-0.8% | $1B-2.4% | |
| Other | $85M-35.1% | $92M-31.9% | $108M-19.4% | $118M-11.3% | $131M-5.8% | |
| U.S. | $1.55B-4.0% | $1.6B+2.0% | $1.65B+5.1% | $1.64B+6.5% | $1.61B+6.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Organon break its business down?
- Organon (OGN) reports revenue by product across 33 parts — Arcoxia, Atozet, Brenzys, Clarinex and Cozaar/Hyzaar. Each is extracted from the segment footnotes and tracked over time.
- Where does Organon's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Organon's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.